Program
pimicotinib
Also written as “pimicotinib capsules”, “ABSK021” and “Pimicotinib”.
Its studies are mostly in Giant Cell Tumor of Tendon Sheath · Synovitis, Pigmented Villonodular · Neoplasms · Pancreatic Neoplasms, led by 2 companies.
Drug pagePimicotinib: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Abbisko Caymanits history only | 135 open or running | phase 3since Mar 13, 2023 | Nov 27, 2019 | Dec 31, 2031phase 1 · NCT04192344 |
| Merck KGaA, Darmstadt, Germanyits history only | 11 open or running | phase 2since Mar 23, 2026 | Mar 23, 2026 | Aug 22, 2028phase 2 · NCT07499362 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 1 study since Nov 27, 2019.
- Mar 7, 2022Phase 1 study in NeoplasmsAbbisko Cayman · NCT05280483 · 16 enrolled · China
- Mar 13, 2023Phase 3 study in Giant Cell Tumor of Tendon SheathAbbisko Cayman · NCT05804045 · 94 enrolled · United States, Canada, China and more
- Aug 6, 2023Named pimicotinibINNProposed as its International Nonproprietary Name in WHO's List 129 · before, ABSK021
- Oct 20, 2023Phase 2 study in Advanced Pancreatic CancerAbbisko Cayman · NCT06111274 · 82 planned · China
- Nov 20, 2023Phase 1 study in Healthy SubjectsAbbisko Cayman · NCT06186583 · 6 enrolled · China
- Nov 28, 2023Phase 2 study in cGvHDAbbisko Cayman · NCT06186804 · 64 planned · China
- Feb 29, 2024Phase 1 study in Healthy SubjectsAbbisko Cayman · NCT06322706 · 36 enrolled · China
- Aug 18, 2024Phase 1 study in PharmacokineticsAbbisko Cayman · NCT06562946 · 24 enrolled · China
- Nov 14, 2024Phase 1 study in PharmacokineticsAbbisko Cayman · NCT06694948 · 26 enrolled · China
- Jan 9, 2025Phase 1 study in Healthy SubjectsAbbisko Cayman · NCT06779253 · 39 enrolled · China
- Mar 13, 2025Phase 1 study in Healthy SubjectsAbbisko Cayman · NCT06884072 · 16 enrolled · China
- Aug 3, 2025Phase 1 study in PharmacokineticsAbbisko Cayman · NCT07126249 · 38 enrolled · China
- Sep 30, 2025Phase 1 study in Pharmacokinetics in Healthy VolunteersAbbisko Cayman · NCT07210996 · 20 enrolled · China
- Mar 23, 2026Merck KGaA, Darmstadt, Germany’s first study: phase 2 study in Giant Cell Tumor of Tendon SheathNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT07499362 · 20 planned · Japan
- Nov 9, 2026Primary completion moved from 2026-12-31 to 2031-12-31Date moved laterphase 1 · +60 months · NCT04192344
Ahead
- Aug 22, 2028Primary completion: phase 2 study in Giant Cell Tumor of Tendon SheathMerck KGaA, Darmstadt, Germany · NCT07499362
- Dec 31, 2031Primary completion: phase 1 study in NeoplasmsAbbisko Cayman · NCT04192344
TargetBeta
“An orally bioavailable inhibitor of colony stimulating factor 1 receptor (CSF1R; CSF-1R; CD115; M-CSFR), ”NCIt, by rule
Other programs on CSF1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| quizartinibrule | Daiichi Sankyo | phase 3 | 22 |
| axatilimabrule | Incyte | phase 3 | 12 |
| vimseltinibrule | Ono Pharmaceutical | phase 3 | 8 |
| seralutinibrule | gb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-inc | phase 3 | 8 |
| adrixetinibrule | qurient-co-ltd | phase 2 | 3 |
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07499362Giant Cell Tumor of Tendon Sheath · Japan | 2 | Recruiting | Merck KGaA, Darmstadt, Germany | Aug 22, 2028 | 20 |
| NCT07210996Pharmacokinetics in Healthy Volunteers · China | 1 | Completed | Abbisko Cayman | Oct 6, 2025 | 20 |
| NCT07126249Pharmacokinetics · China | 1 | Completed | Abbisko Cayman | Jun 6, 2025 | 38 |
| NCT06884072Healthy Subjects · China | 1 | Active, not recruiting | Abbisko Cayman | Jul 1, 2025 | 16 |
| NCT06779253Healthy Subjects · China | 1 | Completed | Abbisko Cayman | Apr 4, 2025 | 39 |
| NCT06694948Pharmacokinetics · China | 1 | Completed | Abbisko Cayman | Jan 3, 2025 | 26 |
| NCT06562946Pharmacokinetics · China | 1 | Completed | Abbisko Cayman | Dec 30, 2024 | 24 |
| NCT06322706Healthy Subjects · China | 1 | Completed | Abbisko Cayman | Nov 1, 2024 | 36 |
| NCT06186804cGvHD · China | 2 | By invitation | Abbisko Cayman | Oct 30, 2026 | 64 |
| NCT06186583Healthy Subjects · China | 1 | Completed | Abbisko Cayman | May 30, 2024 | 6 |
| NCT06111274Advanced Pancreatic Cancer · China | 2 | Recruiting | Abbisko Cayman | Dec 30, 2025 | 82 |
| NCT05804045Giant Cell Tumor of Tendon Sheath · United States, Canada, China and more | 3 | Active, not recruiting | Abbisko Cayman | Sep 23, 2024 | 94 |
| NCT05280483Neoplasms · China | 1 | Completed | Abbisko Cayman | Aug 31, 2022 | 16 |
| NCT04192344Neoplasms · United States, China | 1 | Recruiting | Abbisko Cayman | Dec 31, 2031 | 276 |
How it is read
Names in the registry
- “pimicotinib capsules”, 4 entries
- “ABSK021”, 3 entries
- “Pimicotinib”, 2 entries
- “Pimicotinib(ABSK021)”, 1 entry
- “Pimicotinib capsule”, 1 entry
Codes read as this program: ABSK021.
Conditions, from the studies’ own filings
- Giant Cell Tumor of Tendon Sheath, 2 studies
- Synovitis, Pigmented Villonodular, 1 study
- Neoplasms, 1 study
- Pancreatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.